The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksDiaceutics Regulatory News (DXRX)

Share Price Information for Diaceutics (DXRX)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 99.50
Bid: 98.00
Ask: 101.00
Change: 0.50 (0.51%)
Spread: 3.00 (3.061%)
Open: 99.00
High: 100.00
Low: 99.50
Prev. Close: 99.00
DXRX Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Result of AGM

19 May 2020 14:29

RNS Number : 3820N
Diaceutics PLC
19 May 2020
 

 

19 May 2020

Diaceutics PLC

("Diaceutics" or the "Company")

 

Results of Annual General Meeting

 

Diaceutics PLC (AIM: DXRX), the diagnostic commercialisation company, announces that all resolutions proposed at its Annual General Meeting held earlier today, were duly passed.

 

Details of the proxy votes received on each resolution by Diaceutics' Registrar are set out below:

Resolution

For &Discretionary

Against

Withheld

Total votes cast

Number of votes

%

Number of votes

%

Number of votes

1

Ordinary resolution to receive and consider the 2019 Financial Statements

50,023,247

100.00%

0

0.00%

0

50,023,247

2

Ordinary resolution to re-elect Julie Goonewardene as a director

49,984,878

99.92%

38,369

0.08%

0

50,023,247

3

Ordinary resolution to re-elect Charles Hindson as a director

49,969,009

100.00%

0

0.00%

54,238

49,969,009

4

Ordinary resolution to re-elect Mike Wort as a director

49,969,009

100.00%

0

0.00%

54,238

49,969,009

5

Ordinary resolution to re-elect Peter Keeling as a director

50,023,247

100.00%

0

0.00%

0

50,023,247

6

Ordinary resolution to re-elect Ryan Keeling as a director

49,984,878

99.92%

38,369

0.08%

0

50,023,247

7

Ordinary resolution to re-elect Philip White as a director

50,023,247

100.00%

0

0.00%

0

50,023,247

8

Ordinary resolution to re-appoint PricewaterhouseCoopers LLP as auditors

49,984,878

100.00%

0

0.00%

38,369

49,984,878

9

Ordinary resolution to authorise the directors to determine the remuneration of the auditors

50,007,378

100.00%

0

0.00%

15,869

50,007,378

10

Ordinary resolution to authorise the directors to allot shares

49,984,878

99.92%

38,369

0.08%

0

50,023,247

11

Special resolution to authorise the directors to disapply pre-emption rights

49,983,480

99.92%

39,767

0.08%

0

50,023,247

12

Special resolution to authorise the directors to purchase own shares

47,744,794

99.92%

39,453

0.08%

2,239,000

47,784,247

 

 

 

Enquiries

 

Diaceutics PLC 

 

Stuart Hunt, Head of Investor Relations 

Tel: +44 (0)7815 778 536 

 

 

Cenkos Securities PLC (Nomad & Broker)

Tel: +44(0)20 7397 8900

Callum Davidson / Giles Balleny

 

Michael Johnson (Sales)

 

 

 

Walbrook PR 

Tel: +44 (0)20 7933 8780 or diaceutics@walbrookpr.com

Anna Dunphy 

Tel: +44 (0)7876 741 001 

Paul McManus 

Tel: +44 (0)7980 541 893 

 

 

 

About Diaceutics

Diaceutics PLC is the diagnostic commercialisation company for global pharmaceutical companies. The Company, quoted on the Alternative Investment Market (AIM) of the London Stock Exchange, is enabling pharma to accelerate their market penetration and achieve a better return on precision medicine therapies by helping them to revolutionise patient testing. By generating insights from its data lake of clinical laboratory testing data and other data, Diaceutics helps pharma understand and leverage the diagnostic landscape through initiatives that improve patient testing, leading to better treatment outcomes. The Company works with more than 35 global pharmaceutical companies across hundreds of precision medicine projects. The Company employs a leading global group of experts from the laboratory, diagnostic and pharmaceutical industries. www.diaceutics.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
RAGZZGMKFLNGGZM
Date   Source Headline
13th Mar 202310:12 amRNSFurther update regarding Silicon Valley Bank
13th Mar 20237:30 amRNSSuspension - Diaceutics PLC
13th Mar 20237:00 amRNSUpdate regarding Silicon Valley Bank
1st Mar 20231:57 pmRNSPDMR Shareholding/Share Incentive Plan
30th Jan 20235:11 pmRNSPDMR Shareholding/Share Incentive Plan
26th Jan 20237:00 amRNSUSD 7m enterprise engagements for data services
26th Jan 20237:00 amRNSTrading Statement and Strategy Update
3rd Jan 20237:00 amRNSPDMR Shareholding/Share Incentive Plan
29th Nov 20227:00 amRNSChange of Auditor
29th Nov 20227:00 amRNSPDMR Shareholding/Share Incentive Plan
1st Nov 20227:00 amRNSSub-optimal testing impacts on cancer patients
31st Oct 20222:20 pmRNSPDMR Shareholding/Share Incentive Plan
5th Oct 20225:03 pmRNSPDMR Shareholding/Share Incentive Plan
5th Oct 20227:00 amRNSPurchase of Shares and PDMR Shareholding
27th Sep 20227:00 amRNSHalf-year Report
12th Sep 202212:38 pmRNSPDMR Shareholding/Share Incentive Plan
8th Sep 20227:00 amRNSNotice of Results and Presentations
8th Aug 20227:00 amRNSPDMR Shareholding/Share Incentive Plan
26th Jul 20227:00 amRNSTrading Update and Notice of Results
22nd Jul 20225:45 pmRNSPDMR Shareholding/Share Incentive Plan
13th Jun 20227:00 amRNSMulti-year contract with top five global pharma
7th Jun 20227:00 amRNSNew AI and ML Capabilities Enhance DXRX Platform
31st May 202212:12 pmRNSPDMR Shareholding/Share Incentive Plan
27th May 20224:31 pmRNSShare Options and PDMR Shareholdings
26th May 20223:00 pmRNSResult of AGM
11th May 20222:34 pmRNSPDMR Shareholding/Share Incentive Plan
9th May 20224:37 pmRNSExercise of Warrant & Total Voting Rights
5th May 20227:00 amRNSContract Win
29th Apr 20225:22 pmRNSPDMR Shareholding/Share Incentive Plan
28th Apr 20222:09 pmRNSNotice of AGM and Posting of Annual Report
7th Apr 20227:00 amRNSPurchase and Sale of Shares and PDMR Shareholdings
6th Apr 20221:13 pmRNSPDMR Shareholding/Share Incentive Plan
5th Apr 20223:49 pmRNSConversion of Convertible Loan Notes & TVR
1st Apr 20227:00 amRNSIssue of Share Options / PDMR Shareholdings
31st Mar 20225:38 pmRNSPDMR Shareholding/Share Incentive Plan
22nd Mar 20222:43 pmRNSFinal Results
22nd Mar 20227:00 amRNSNotice of 2021 Full Year Results
18th Mar 20222:09 pmRNSConfirmation of Directorate Change
16th Mar 20225:49 pmRNSHolding(s) in Company
16th Mar 20227:00 amRNSApproval by CMS for enhanced data access
2nd Mar 20225:37 pmRNSPDMR Shareholding/Share Incentive Plan
21st Feb 20227:00 amRNSInvestor Presentation
14th Feb 20226:26 pmRNSPDMR Shareholding/Share Incentive Plan
14th Feb 20227:00 amRNSContract with leading life sciences company
4th Feb 202211:26 amRNSDirector/PDMR Shareholding
11th Jan 20227:01 amRNSDirectorate Change
11th Jan 20227:00 amRNSTrading Update and Notice of Results
4th Jan 20227:00 amRNSPDMR Shareholding/Share Incentive Plan
14th Dec 20217:00 amRNSContract Win
9th Dec 20217:00 amRNSTest Signal Launch and Contract Wins

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.